Precision Radiotherapy for Liver and Pancreatic Malignancies: Indications, Techniques and Response Evaluation (PRO 09)

This activity focuses on the multidisciplinary care of liver and pancreatic cancer highlighting the role of radiation therapy. One talk discusses the role of radiation therapy in the hepatocellular carcinoma, focusing on evidence supporting the use of radiotherapy across multiple settings: definitive treatment in early stage, combination therapy in advanced disease, bridge or downstaging to transplant and for palliation. Radiation Oncologists sometimes do not fully engage in the multidisciplinary discussion of these patients with complex and challenging malignancies due to unfamiliarity with the indications for radiation therapy, the integration of RT in the multidisciplinary care and/or due to lack of familiarity in planning and delivery of moving and changing target volumes and organ at risk. One of the talks discusses promising data on the emerging role of dose escalated radiation therapy in the definitive management of locally advanced pancreatic cancer, the use of elective volumes for pancreas SBRT, and also provides learners practical advice on how this can be safely delivered. The third talk discusses the complex imaging changes that occur in the liver after SBRT or hypofractionated radiotherapy. Radiation Oncologists must have this knowledge to discuss with their radiology colleagues to appropriately differentiate what are expected post treatment changes and what may be signs of progression. This session addresses these challenges.

Target Audience

This activity is designed to meet the interests of medical oncologists, radiation oncologists, nurses, radiation therapists, SLP's and dietitians. 

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • To understand practical considerations for safely treating and escalating radiation dose to tumors in the upper abdomen.
  • To increase awareness of trials of radiation therapy in liver and pancreatic cancer.
  • Share practical tips for patient selection, treatment and response evaluation for radiation therapy.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course opens: 
12/01/2025
Course expires: 
12/31/2026
Cost:
$0.00
Rating: 
0
  • Virginia M. Diavolitsis, MD, is employed by Riverside Radiation Oncology Inc.
  • Shauna Rosalie Campbell, DO, is employed by Cleveland Clinic.
  • Carryn M. Anderson, MD, is employed University of Iowa Hospitals and Clinics.
  • Darrion L. Mitchell, MD, PhD, is employed by James Cancer Hospital, The Ohio State University. 

All relevant financial relationships have been mitigated.

The person(s) above served as the developer(s) of this activity. Additionally, the Annual Meeting Steering Committee had control over the content of this activity.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.